Evidence map›Paper›PMID 39633539›Full record

ReviewCurrent opinion in HIV and AIDS2025

Viral and immune predictors of HIV posttreatment control.

Flavio S Mesquita, Yijia Li, Jonathan Z Li

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Maintenance of intestinal CX3CR1Nature communications · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Flavio S MesquitaBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Yijia LiUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Funding

High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Ya-Chi Ho, Jonathan Li · 2022 to 2026
$10.1M
HIV Reservoir Ecology of Viral Remission (PTC)R01AI150396 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, JONATHAN · 2020 to 2025
$5.4M
Fostering diversity in the next generation of HIV researchers to improve the HIV continuum of careR25MH119857 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2020 to 2024
$1.5M
HIV Reservoir Ecology of Viral Remission (PTC)R37AI150396 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Jonathan Li · 2026 to 2026
$868k
NIAID NIH HHS P01 AI169768NIAID NIH HHS R01 AI150396NIAID NIH HHS R37 AI150396NIMH NIH HHS R25 MH119857
6 · The paper itself

Abstract

purpose of reviewThis review focuses on the viral and immune factors influencing HIV posttreatment control (PTC), a rare condition where individuals maintain viral suppression after discontinuing antiretroviral therapy (ART). RECENT

findingsStudies demonstrate that early ART initiation leads to smaller HIV reservoirs and delayed viral rebound in PTCs. Virologically, PTCs harbor smaller HIV reservoirs and show lower levels of reservoir transcriptional activity compared with posttreatment noncontrollers. Immunologically, PTCs exhibit distinct T-cell dynamics, with reduced CD4+ and CD8+ T-cell activation and exhaustion, enhanced natural killer (NK) cell activity, and enhanced proliferative responses of HIV-specific CD8+ T cells post-ART interruption. Additionally, humoral immunity, particularly the development of autologous neutralizing antibodies (aNAbs), plays a role in viral control, though broadly neutralizing antibodies (bnAbs) are rare. SUMMARY: The mechanisms behind posttreatment control are multifactorial, involving virological and immunological factors. Early ART initiation, a smaller and less transcriptionally active HIV reservoir, and immune responses including proliferative T-cell activity and NK cell function are key contributors to achieving ART-free HIV remission.

Indexed as

HIV InfectionsAntibodies, NeutralizingAnti-HIV AgentsAnti-Retroviral AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV-1HIV AntibodiesHumansKiller Cells, NaturalViral LoadAntibodies, NeutralizingAnti-HIV AgentsAnti-Retroviral AgentsHIV Antibodies

Identifiers

PMID39633539
PMCPMC13157257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.